SHATTUCK LABS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.59 USD | +8.28% |
|
+10.54% | +48.53% |
| Mar. 04 | Shattuck Labs, Inc. Announces Board Appointments | CI |
| Mar. 01 | Sector Update: Health Care Stocks Rising Late Afternoon | MT |
Financials (USD)
| Sales 2024 * | 811K | Sales 2025 * | - | Capitalization | 465M |
|---|---|---|---|---|---|
| Net income 2024 * | -91M | Net income 2025 * | -108M | EV / Sales 2024 * | 573 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-5.6
x | P/E ratio 2025 * |
-5.28
x | Employees | 75 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Shattuck Labs, Inc.
More recommendations
More press releases
| 1 day | +8.28% | ||
| 1 week | +10.54% | ||
| Current month | +18.46% | ||
| 1 month | +19.66% | ||
| 3 months | +6.65% | ||
| 6 months | +536.04% | ||
| Current year | +48.53% |
1 week
9.22
10.64
1 month
8.5510.64
Current year
6.9811.11
1 year
1.3311.11
3 years
1.3338.90
5 years
1.3360.52
10 years
1.3360.52
| Managers | Title | Age | Since |
|---|---|---|---|
Taylor Schreiber
FOU | Founder | 44 | 15-12-31 |
Andrew Neill
DFI | Director of Finance/CFO | 38 | 19-06-30 |
Stephen Stout
CMP | Compliance Officer | 49 | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Neil Gibson
BRD | Director/Board Member | 67 | 16-10-31 |
| Chairman | 67 | 17-12-31 | |
Michael Lee
BRD | Director/Board Member | 45 | 20-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 10.59 | +8.28% | 381,451 |
| 24-04-25 | 9.78 | -1.21% | 112,347 |
| 24-04-24 | 9.9 | +4.32% | 234,436 |
| 24-04-23 | 9.49 | +2.04% | 319,256 |
| 24-04-22 | 9.3 | -2.92% | 307,188 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
9.78
USD
Average target price
15.75
USD
Spread / Average Target
+61.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +48.53% | 465M | |
| +1.51% | 42.59B | |
| +8.57% | 40.65B | |
| +49.22% | 40.57B | |
| -12.36% | 26.77B | |
| +8.92% | 24.81B | |
| -25.13% | 18.17B | |
| +29.17% | 12.05B | |
| -3.12% | 11.7B | |
| +6.35% | 11.1B |
- Stock Market
- Equities
- STTK Stock
